Colorectal carcinomas, KRAS p.G13D mutant allele–specific imbalance, and anti–epidermal growth factor receptor therapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|119|24|4366-4366

ISSN： 0008-543x

Source： CANCER, Vol.119, Iss.24, 2013-12, pp. : 4366-4366

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Reply to colorectal carcinomas, KRAS p.G13D mutant allele–specific imbalance, and anti–epidermal growth factor receptor therapy

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4366-4367

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey Results

By  

Oncology, Vol. 72, Iss. 3-4, 2007-12 ,pp. : 152-159

Karger

Access to resources Recommend Favorite

Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 225 Upregulates p27KIP1 and p15INK4B and Induces G1 Arrest in Oral Squamous Carcinoma Cell Lines

By  

Oncology, Vol. 63, Iss. 1, 2002-08 ,pp. : 92-98

Karger

Access to resources Recommend Favorite

Effects of the Anti-Epidermal Growth Factor Receptor Antibody Cetuximab on Cholangiocarcinoma of the Liver

By  

Oncology Research and Treatment, Vol. 30, Iss. 3, 2007-02 ,pp. : 129-131

Karger

Access to resources Recommend Favorite

Clinical and Economic Aspects of KRAS Mutational Status as Predictor for Epidermal Growth Factor Receptor Inhibitor Therapy in Metastatic Colorectal Cancer Patients

By  

Oncology, Vol. 81, Iss. 5-6, 2012-01 ,pp. : 359-364

Karger

Access to resources Recommend Favorite